The ST2/Interleukin-33 Axis in Hematologic Malignancies: The IL-33 Paradox
Open Access
- 22 October 2019
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (20), 5226
- https://doi.org/10.3390/ijms20205226
Abstract
Interleukin (IL)-33 is a chromatin-related nuclear interleukin that is a component of IL-1 family. IL-33 production augments the course of inflammation after cell damage or death. It is discharged into the extracellular space. IL-33 is regarded as an “alarmin” able to stimulate several effectors of the immune system, regulating numerous immune responses comprising cancer immune reactions. IL-33 has been demonstrated to influence tumorigenesis. However, as far as this cytokine is concerned, we are faced with what has sometimes been defined as the IL-33 paradox. Several studies have demonstrated a relevant role of IL-33 to numerous malignancies, where it may have pro- and—less frequently—antitumorigenic actions. In the field of hematological malignancies, the role of IL-33 seems even more complex. Although we can affirm the existence of a negative role of IL-33 in Chronic myelogenos leukemia (CML) and in lymphoproliferative diseases and a positive role in pathologies such as Acute myeloid leukemia (AML), the action of IL-33 seems to be multiple and sometimes contradictory within the same pathology. In the future, we will have to learn to govern the negative aspects of activating the IL-33/ST2 axis and exploit the positive ones.This publication has 110 references indexed in Scilit:
- IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin GProceedings of the National Academy of Sciences of the United States of America, 2012
- IL‐33 synergizes with TCR and IL‐12 signaling to promote the effector function of CD8+ T cellsEuropean Journal of Immunology, 2011
- Identification of Constitutively Active Interleukin 33 (IL-33) Splice VariantOnline Journal of Public Health Informatics, 2011
- Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanomaThe Journal of Experimental Medicine, 2010
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TANCancer Cell, 2009
- The NLRP3 inflammasome: A sensor of immune danger signalsSeminars in Immunology, 2009
- The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1Proceedings of the National Academy of Sciences of the United States of America, 2009
- Cancer-related inflammationNature, 2008
- IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factorin vivoProceedings of the National Academy of Sciences of the United States of America, 2007
- Individual Vγ2-Jγ1.2+ T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigensCancer Immunology, Immunotherapy, 2006